{"transactions":[{"id":4623779,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-21T22:40:40.000Z","date":"2026-09-17","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2026-10-18","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-396944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526396944/ownership.xml","form_type":"4"}},{"id":4623778,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-21T22:40:40.000Z","date":"2026-09-17","kind":"sale","planned":false,"acquired":false,"shares":13679,"price":57.0901,"value":780935.4779,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.97 to $57.43 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":16637,"source":{"system":"sec-edgar","filing":"0001193125-26-396944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526396944/ownership.xml","form_type":"4"}},{"id":4623777,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-21T22:40:40.000Z","date":"2026-09-17","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":14,"value":420000.0,"ownership":{"direct":true},"balance_after":30316,"source":{"system":"sec-edgar","filing":"0001193125-26-396944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526396944/ownership.xml","form_type":"4"}},{"id":4623749,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-21T22:30:10.000Z","date":"2025-08-06","kind":"other","planned":false,"acquired":true,"shares":15,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Ali Behbahani Revocable Trust Dated June 26, 2015 (the \"Behbahani Trust\") received 15 Common Shares of the Issuer in the distribution by NEA Partners 15 on August 6, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is the trustee of the Behbahani Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, of such portion of the Common Shares of the Issuer held by the Behbahani Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":29,"source":{"system":"sec-edgar","filing":"0001193125-26-396935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526396935/ownership.xml","form_type":"4"}},{"id":4623748,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-21T22:30:10.000Z","date":"2025-08-06","kind":"other","planned":false,"acquired":true,"shares":60,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"NEA Partners 15, L.P. (\"NEA Partners 15\") made a pro rata distribution for no consideration of Common Shares of the Issuer to its limited partners on August 6, 2025. The Reporting Person received 60 Common Shares of the Issuer in the distribution by NEA Partners 15 on August 6, 2025."}],"balance_after":316,"source":{"system":"sec-edgar","filing":"0001193125-26-396935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526396935/ownership.xml","form_type":"4"}},{"id":4623642,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-21T21:45:30.000Z","date":"2026-09-18","kind":"grant","planned":false,"acquired":true,"shares":7707,"price":1.93,"value":14874.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026."}],"balance_after":110236,"source":{"system":"sec-edgar","filing":"0001193125-26-396868","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526396868/ownership.xml","form_type":"4"}},{"id":714466,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:57:07.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"NEA Partners 17 made a distribution of 15,000 shares of Common Stock of the Issuer for no consideration on July 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-296490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526296490/ownership.xml","form_type":"4"}},{"id":714465,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:57:07.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"NEA Partners 17 received 15,000 shares of Common Stock of the Issuer in the distribution made by NEA 17 on July 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001193125-26-296490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526296490/ownership.xml","form_type":"4"}},{"id":714464,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:57:07.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 17, L.P. (\"NEA 17\") made a pro rata distribution of 1,000,000 shares of Common Stock of the Issuer to its general partner and limited partners for no consideration on July 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC (\"NEA 17 GP\"), which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of NEA 17, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6692298,"source":{"system":"sec-edgar","filing":"0001193125-26-296490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526296490/ownership.xml","form_type":"4"}},{"id":723995,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:40:15.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-288598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526288598/ownership.xml","form_type":"4"}},{"id":730511,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:19:12.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":8961,"price":1.66,"value":14875.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026."}],"balance_after":102529,"source":{"system":"sec-edgar","filing":"0001193125-26-277553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526277553/ownership.xml","form_type":"4"}},{"id":739172,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T22:44:45.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526269885/ownership.xml","form_type":"4"}},{"id":741209,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T22:10:20.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":14677,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":14677,"derivative":{"exercise_price":10.59,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":14677},"source":{"system":"sec-edgar","filing":"0001193125-26-268018","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526268018/ownership.xml","form_type":"4"}},{"id":741208,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:27:06.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares subject to the option vest 100% on the first to occur of (i) June 10, 2027 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a \"change in control\" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or \"disability\" (as described in the applicable award agreement)."}],"balance_after":37000,"derivative":{"exercise_price":2.46,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001193125-26-267632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526267632/ownership.xml","form_type":"4"}},{"id":744664,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-09T22:06:29.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting."}],"balance_after":13000,"derivative":{"exercise_price":51.84,"expiration_date":"2036-06-05","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001193125-26-264382","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000119312526264382/ownership.xml","form_type":"4"}},{"id":798589,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:34:28.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9174,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":63.68,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9174},"source":{"system":"sec-edgar","filing":"0001193125-26-187305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526187305/ownership.xml","form_type":"4"}},{"id":798588,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:34:28.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":51.3,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":8011},"source":{"system":"sec-edgar","filing":"0001193125-26-187305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526187305/ownership.xml","form_type":"4"}},{"id":798587,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:34:28.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11459,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":37.94,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":11459},"source":{"system":"sec-edgar","filing":"0001193125-26-187305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526187305/ownership.xml","form_type":"4"}},{"id":798586,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-28T20:34:28.000Z","date":"2026-04-28","kind":"other","planned":false,"acquired":false,"shares":2706,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the \"Merger Agreement\"), by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (\"Closing Amount\"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a \"CVR\"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a trustee of the Ali Behbahani Revocable Trust Dated June 26, 2015 (the \"Behbahani Trust\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Behbahani Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-187305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526187305/ownership.xml","form_type":"4"}},{"id":798585,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-28T20:34:28.000Z","date":"2026-04-28","kind":"other","planned":false,"acquired":false,"shares":1925,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the \"Merger Agreement\"), by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (\"Closing Amount\"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a \"CVR\"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-187305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526187305/ownership.xml","form_type":"4"}},{"id":832331,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-20T21:27:25.000Z","date":"2026-03-20","kind":"grant","planned":false,"acquired":true,"shares":6919,"price":2.15,"value":14875.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026."}],"balance_after":93568,"source":{"system":"sec-edgar","filing":"0001193125-26-117938","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526117938/ownership.xml","form_type":"4"}},{"id":845506,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants","published_at":"2026-03-13T00:15:10.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":242945,"price":11.109,"value":2698876.005,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":242945,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":242945},"source":{"system":"sec-edgar","filing":"0001193125-26-104718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526104718/ownership.xml","form_type":"4"}},{"id":845505,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T00:15:10.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":207100,"price":11.11,"value":2300881.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1297893,"source":{"system":"sec-edgar","filing":"0001193125-26-104718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526104718/ownership.xml","form_type":"4"}},{"id":904728,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T21:30:19.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051545","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051545/ownership.xml","form_type":"5"}},{"id":904727,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T21:30:19.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051545/ownership.xml","form_type":"5"}},{"id":909524,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":402273},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909523,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":954990},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909522,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":737962},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909521,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909520,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1370168},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909519,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":false,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1619240},"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909518,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":402273,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1357263,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909517,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":954990,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":954990,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909516,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"purchase","planned":false,"acquired":true,"shares":937500,"price":16,"value":15000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6035038,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909515,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":737962,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":5097538,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909514,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":4359576,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909513,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1370168,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":2989408,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":909512,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-11T21:30:25.000Z","date":"2026-02-09","kind":"exercise","planned":false,"acquired":true,"shares":1619240,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share (\"Common Stock\"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1619240,"source":{"system":"sec-edgar","filing":"0001193125-26-046676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526046676/ownership.xml","form_type":"4"}},{"id":914024,"issuer":{"id":5034,"kind":"organization","name":"SpyGlass Pharma, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-09T21:58:48.000Z","date":"2026-02-05","kind":"grant","planned":false,"acquired":true,"shares":27400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). \"Date of Grant\" shall mean February 5, 2026."}],"balance_after":27400,"derivative":{"exercise_price":16,"expiration_date":"2036-02-05","underlying":"Common Stock","underlying_shares":27400},"source":{"system":"sec-edgar","filing":"0001193125-26-042980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526042980/ownership.xml","form_type":"4"}},{"id":969505,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-15T21:39:20.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":5208,"price":2.76,"value":14374.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025."}],"balance_after":86649,"source":{"system":"sec-edgar","filing":"0001193125-25-319303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312525319303/ownership.xml","form_type":"4"}},{"id":1023077,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1352200},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023076,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":550323},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023075,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":124085,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023074,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":124085,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":124085,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":124085},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023073,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":607536,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"The warrants became exercisable as to 371,187 shares on April 30, 2024, 28,399 shares on June 21, 2024, 185,595 shares on October 2, 2024 and 22,355 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":607536},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023072,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":1656789,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The warrants became exercisable as to 828,395 shares on August 29, 2023, 552,263 shares on September 18, 2023, 100,606 shares on November 1, 2023 and 175,525 shares on December 20, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":1656789},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023071,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37700,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The Series B Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $1.4169 per share) as of the conversion date, subject to anti-dilution adjustments. The Series B Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series B Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509780},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023070,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Perpetual Preferred Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The Series A Preferred Stock was convertible into the number of shares of the Issuer's Common Stock equal to the quotient of (a) the sum of (i) the liquidation preference (initially $1,000 per share) plus (ii) the accrued dividends thereon as of the conversion date, divided by (b) the conversion price (initially approximately $4.55 per share) as of the conversion date, subject to anti-dilution adjustments. The Series A Preferred Stock was convertible at any time and had no expiration date, subject to the Issuer's election to convert or redeem all of the Series A Preferred Stock upon the occurrence of certain conditions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":330194},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023069,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":186128,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023068,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":186128,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":186128,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":186128},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023067,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":189195,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":189195},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023066,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":false,"shares":372255,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The warrants became fully exercisable on October 2, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":372255},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023065,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":372255,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Warrants issued pursuant to the Warrantholders Agreement, dated September 30, 2025 between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, that certain Incremental Amendment No. 2, dated as of April 8, 2024, that certain Amendment No. 3, dated as of June 21, 2024, that certain Amendment No. 4, dated as of October 29, 2024, and that certain Amendment No. 5, dated as of September 30, 2025, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":372255,"derivative":{"exercise_price":0.01,"exercise_date":"2025-10-02","expiration_date":"2030-10-02","underlying":"Common Stock","underlying_shares":372255},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023064,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":false,"shares":189195,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The warrants became exercisable as to 123,729 shares on April 30, 2024, 1,733 shares on June 21, 2024, 61,865 shares on October 2, 2024 and 1,868 shares on September 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":189195},"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023063,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2384873,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023062,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":182,"price":6.75,"value":1228.5,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2384873,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023061,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":124085,"price":0.01,"value":1240.85,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2385055,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023060,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":900,"price":6.75,"value":6075.0,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2260970,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023059,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":607536,"price":0.01,"value":6075.36,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":2261870,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023058,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":2455,"price":6.75,"value":16571.25,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1654334,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023057,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":1656789,"price":0.01,"value":16567.89,"ownership":{"direct":false,"nature":"See Note 5"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":1656789,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023056,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":674554,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023055,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":276,"price":6.75,"value":1863.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674554,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023054,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":186128,"price":0.01,"value":1861.28,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":674830,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023053,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":280,"price":6.75,"value":1890.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488702,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023052,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":189195,"price":0.01,"value":1891.95,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":488982,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023051,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1159683,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Agreement and Plan of Merger, dated as of December 23, 2024, by and among the Issuer, NH Holdings 2025, Inc. (\"Parent\") and NH Holdings Acquisition 2025, Inc. (\"Merger Sub\"), on October 2, 2025, Merger Sub merged with and into the Issuer with the Issuer surviving such merger as a wholly owned subsidiary of Parent (the \"Merger\"). Pursuant to rollover agreements entered into between certain of the Reporting Persons and NH Holdings 2025 SPV, L.P. (\"Ultimate Parent\"), Parent and Merger Sub, each share of the Issuer's Common Stock, Series A Convertible Perpetual Preferred Stock (\"Series A Preferred Stock\") and Series B Convertible Perpetual Preferred Stock (\"Series B Preferred Stock\") beneficially owned by the Reporting Persons was contributed to Ultimate Parent in exchange for limited partnership interests in Ultimate Parent. Each such share of the Issuer's Common Stock, Series A Preferred Stock and Series B Preferred Stock was then cancelled and ceased to exist."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023050,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":551,"price":6.75,"value":3719.25,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1159683,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023049,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"exercise","planned":false,"acquired":true,"shares":372255,"price":0.01,"value":3722.55,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":1160234,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023048,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"sale","planned":false,"acquired":false,"shares":280,"price":6.75,"value":1890.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $6.75 per share, the closing market price of the Issuer's common stock on October 1, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":787979,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1023047,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-06T21:52:01.000Z","date":"2025-10-02","kind":"other","planned":false,"acquired":true,"shares":189195,"price":0.01,"value":1891.95,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":788259,"source":{"system":"sec-edgar","filing":"0001193125-25-232141","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000119312525232141/ownership.xml","form_type":"4"}},{"id":1034594,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T21:58:01.000Z","date":"2025-09-19","kind":"grant","planned":false,"acquired":true,"shares":4291,"price":3.35,"value":14374.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 18, 2025."}],"balance_after":81441,"source":{"system":"sec-edgar","filing":"0001193125-25-211678","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312525211678/ownership.xml","form_type":"4"}},{"id":1061205,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares with a nominal value of 0.001 GBP per share","published_at":"2025-08-19T23:07:09.000Z","date":"2025-08-18","kind":"sale","planned":false,"acquired":false,"shares":14671794,"price":0.012,"value":176061.528,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares whose sale is reported in this row are represented by American Depositary Shares (\"ADSs\") and are held of record by New Enterprise Associates 16, L.P. (\"NEA 16\"). NEA 16 holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.012 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0114 to $0.0130 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC (\"NEA 16 GP\"), which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-110254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025110254/ownership.xml","form_type":"4"}},{"id":1061204,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares with a nominal value of 0.001 GBP per share","published_at":"2025-08-19T23:07:09.000Z","date":"2025-08-15","kind":"sale","planned":false,"acquired":false,"shares":4828206,"price":0.011,"value":53110.266,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares whose sale is reported in this row are represented by American Depositary Shares (\"ADSs\") and are held of record by New Enterprise Associates 16, L.P. (\"NEA 16\"). NEA 16 holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.011 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0099 to $0.0118 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 16 GP, LLC (\"NEA 16 GP\"), which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":14671794,"source":{"system":"sec-edgar","filing":"0000950170-25-110254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025110254/ownership.xml","form_type":"4"}},{"id":1066118,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T22:22:46.000Z","date":"2025-08-12","kind":"other","planned":false,"acquired":true,"shares":2621,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Ali Behbahani Revocable Trust Dated June 26, 2015 (the \"Behbahani Trust\") received 2,621 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on August 12, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a trustee of the Behbahani Trust, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the 1934 Act, as amended, or otherwise of such portion of the securities held by the Behbahani Trust in which the Reporting Person has no pecuniary interest."}],"balance_after":2706,"source":{"system":"sec-edgar","filing":"0000950170-25-109112","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025109112/ownership.xml","form_type":"4"}},{"id":1066117,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T22:22:46.000Z","date":"2025-08-12","kind":"other","planned":false,"acquired":true,"shares":1586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"NEA Partners 15, L.P. (\"NEA Partners 15\") made a pro rata distribution for no consideration of shares of Common Stock of the Issuer to its limited partners on August 12, 2025. The Reporting Person received 1,586 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on August 12, 2025."}],"balance_after":1925,"source":{"system":"sec-edgar","filing":"0000950170-25-109112","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025109112/ownership.xml","form_type":"4"}},{"id":1105040,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:21:52.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":6170,"price":2.33,"value":14376.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025."}],"balance_after":77150,"source":{"system":"sec-edgar","filing":"0000950170-25-088527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017025088527/ownership.xml","form_type":"4"}},{"id":1109409,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:10:47.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025086727/ownership.xml","form_type":"4"}},{"id":1113458,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:34:31.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0000950170-25-085676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017025085676/ownership.xml","form_type":"4"}},{"id":1112876,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:40:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":6010,"derivative":{"exercise_price":14.87,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":6010},"source":{"system":"sec-edgar","filing":"0000950170-25-085495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025085495/ownership.xml","form_type":"4"}},{"id":1117385,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:25:33.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares subject to the option vest 100% on the first to occur of (i) June 5, 2026 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a \"change in control\" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or \"disability\" (as described in the applicable award agreement)."}],"balance_after":46000,"derivative":{"exercise_price":1.83,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0000950170-25-083779","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025083779/ownership.xml","form_type":"4"}},{"id":1119667,"issuer":{"id":3852,"kind":"organization","name":"CRISPR Therapeutics AG","symbol":"CRSP"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T21:38:03.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders."}],"balance_after":13000,"derivative":{"exercise_price":38.57,"expiration_date":"2035-06-05","underlying":"Common Shares","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0000950170-25-083289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025083289/ownership.xml","form_type":"4"}},{"id":1128898,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:33:05.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":9174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 29, 2026 or the next annual meeting of stockholders."}],"balance_after":9174,"derivative":{"exercise_price":63.68,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9174},"source":{"system":"sec-edgar","filing":"0000950170-25-079776","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025079776/ownership.xml","form_type":"4"}},{"id":1194661,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T20:19:30.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":7646,"price":1.88,"value":14374.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 20, 2025."}],"balance_after":70980,"source":{"system":"sec-edgar","filing":"0000950170-25-043221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017025043221/ownership.xml","form_type":"4"}},{"id":1323293,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":66498,"kind":"organization","name":"New Enterprise Associates 16, L.P.","position":1,"cik":"0001694560","reported_name":"New Enterprise Associates 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66499,"kind":"organization","name":"NEA Partners 16, L.P.","position":2,"cik":"0001712881","reported_name":"NEA Partners 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66500,"kind":"organization","name":"NEA 16 GP, LLC","position":3,"cik":"0001712882","reported_name":"NEA 16 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61210,"kind":"person","name":"BASKETT FOREST","position":4,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":38171,"kind":"person","name":"Chang Carmen","position":5,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31983,"kind":"person","name":"Behbahani Ali","position":6,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":7,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":8,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":9,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":61190,"kind":"person","name":"Walker Paul Edward","position":10,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T21:40:48.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":554250,"price":3.2,"value":1773600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the \"Reverse Stock Split\"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are directly held by New Enterprise Associates 16, L.P. (\"NEA 16\"), and indirectly held by NEA Partners 16, L.P. (\"NEA Partners 16\"), the sole general partner of NEA 16, NEA 16 GP, LLC (\"NEA 16 GP\"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the \"Indirect Reporting Persons\").The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi,  Scott D. Sandell, and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares of the Issuer held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":1625678,"source":{"system":"sec-edgar","filing":"0000950170-24-139630","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000095017024139630/ownership.xml","form_type":"4"}},{"id":1330839,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T22:09:54.000Z","date":"2024-12-13","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":2.5,"value":14375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024."}],"balance_after":63334,"source":{"system":"sec-edgar","filing":"0000950170-24-136739","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024136739/ownership.xml","form_type":"4"}},{"id":1392033,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:30:16.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":185595,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 18 VGE GP, LLC, which is the sole general partner of NEA Partners 18 VGE, L.P. (\"NEA Partners 18 VGE\"). NEA Partners 18 VGE is the sole general partner of NEA 18 Venture Growth Equity, L.P. (\"NEA 18 VGE\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 18 VGE in which the Reporting Person has no pecuniary interest."}],"balance_after":556782,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":185595},"source":{"system":"sec-edgar","filing":"0000950170-24-112607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112607/ownership.xml","form_type":"4"}},{"id":1392032,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:30:16.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":61865,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":185594,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":61865},"source":{"system":"sec-edgar","filing":"0000950170-24-112607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112607/ownership.xml","form_type":"4"}},{"id":1392031,"issuer":{"id":74308,"kind":"organization","name":"NeueHealth, Inc.","symbol":"NEUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-03T22:30:16.000Z","date":"2024-10-01","kind":"purchase","planned":false,"acquired":true,"shares":61865,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":185594,"derivative":{"exercise_price":0.01,"exercise_date":"2024-10-02","expiration_date":"2029-04-30","underlying":"Common Stock","underlying_shares":61865},"source":{"system":"sec-edgar","filing":"0000950170-24-112607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671284/000095017024112607/ownership.xml","form_type":"4"}},{"id":1401619,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:30:56.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":3007,"price":4.78,"value":14373.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 19, 2024."}],"balance_after":57584,"source":{"system":"sec-edgar","filing":"0000950170-24-108430","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024108430/ownership.xml","form_type":"4"}},{"id":1405214,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-09-18T00:24:49.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":25142840,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2091383},"source":{"system":"sec-edgar","filing":"0000950170-24-107554","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107554/ownership.xml","form_type":"4"}},{"id":1405213,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-09-18T00:24:49.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":12299854,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1023103},"source":{"system":"sec-edgar","filing":"0000950170-24-107554","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107554/ownership.xml","form_type":"4"}},{"id":1405212,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:24:49.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":16,"value":8000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3614486,"source":{"system":"sec-edgar","filing":"0000950170-24-107554","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107554/ownership.xml","form_type":"4"}},{"id":1405211,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:24:49.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":2091383,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":3114486,"source":{"system":"sec-edgar","filing":"0000950170-24-107554","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107554/ownership.xml","form_type":"4"}},{"id":1405210,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T00:24:49.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":1023103,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the \"Preferred Stock\") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. (\"NEA 17\"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":1023103,"source":{"system":"sec-edgar","filing":"0000950170-24-107554","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017024107554/ownership.xml","form_type":"4"}},{"id":1465483,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T21:10:03.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1144686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of U.S.$1.263714 to GBP1.00.  The actual exercise price will be the pounds sterling amount."}],"balance_after":1144686,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":1144686},"source":{"system":"sec-edgar","filing":"0000950170-24-079752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017024079752/ownership.xml","form_type":"4"}},{"id":1472088,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:25:32.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":2887,"price":4.98,"value":14377.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 20, 2024."}],"balance_after":54577,"source":{"system":"sec-edgar","filing":"0000950170-24-076273","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024076273/ownership.xml","form_type":"4"}},{"id":1478470,"issuer":{"id":6346,"kind":"organization","name":"Nkarta, Inc."},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:30:13.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares subject to the option vest 100% on the first to occur of (i) June 13, 2025 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a \"change in control\" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's  separation from service with the Issuer due to the Reporting Person's death or \"disability\" (as described in the applicable award agreement)."}],"balance_after":22500,"derivative":{"exercise_price":6.23,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-24-073729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017024073729/ownership.xml","form_type":"4"}},{"id":1480207,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T00:12:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":22100,"derivative":{"exercise_price":4.16,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0000950170-24-073265","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017024073265/ownership.xml","form_type":"4"}},{"id":1481706,"issuer":{"id":6388,"kind":"organization","name":"Korro Bio, Inc.","symbol":"KRRO"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T21:30:03.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":5190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service as a non-employee director through the applicable vesting date."}],"balance_after":5190,"derivative":{"exercise_price":42.19,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":5190},"source":{"system":"sec-edgar","filing":"0000950170-24-072567","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017024072567/ownership.xml","form_type":"4"}}],"next_cursor":"2024-06-12T21:30:03.000000Z,1481706"}